HC Wainwright & Co. Reiterates Neutral on Eliem Therapeutics, Maintains $6 Price Target
HC Wainwright & Co. analyst Douglas Tsao reiterates Eliem Therapeutics (NASDAQ:ELYM) with a Neutral and maintains $6 price target.
Eliem Therapeutics Q4 EPS $(0.29) Beats $(0.38) Estimate
Eliem Therapeutics (NASDAQ:ELYM) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(0.38) by 23.68 percent. This is a 27.5 percent increase over losses of $(0.40) per share from
Eliem Therapeutics CEO Robert Azelby, COO And CFO Erin Lavelle Resigned Effective February 13 As It Decides To Cut Workforce By 55%
On February 13, 2023, Eliem entered into a letter agreement with three of its executive officers – President, Chief Executive Officer and Director Robert Azelby, Executive Vice President, Chief Operating
Eliem Pauses Development On Depression Drug, Lays Off 55% Workforce
Eliem Therapeutics Inc (NASDAQ:ELYM) announced reprioritizing its pipeline to focus on its high potential preclinical Kv7.2/3 program (Kv7 Program) and the…
Why Enovix Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Wednesday’s Mid-Day Session
Gainers
Vivos Therapeutics, Inc. (NASDAQ: VVOS) shares surged 204% to $2.25 after the company announced it received FDA 510(k) clearance for its DNA oral appliance for the treatment of obstructive sleep apnea.
HC Wainwright & Co. Initiates Coverage On Eliem Therapeutics with Buy Rating, Announces Price Target of $6
HC Wainwright & Co. analyst Douglas Tsao initiates coverage on Eliem Therapeutics (NASDAQ:ELYM) with a Buy rating and announces Price Target of $6.
Eliem Therapeutics Outlines Interim Data From Early-Stage Depressive Study
Eliem Therapeutics Inc (NASDAQ:ELYM) announced interim results from its ongoing Phase 1 trial of ETX-155 for major depressive disorder (MDD) and…
SVB Leerink Maintains Outperform Rating for Eliem Therapeutics: Here’s What You Need To Know
SVB Leerink has decided to maintain its Outperform rating of Eliem Therapeutics (NASDAQ:ELYM) and lower its price target from $9.00 to $4.00.
Shares of Eliem Therapeutics are trading down 2.08% over the last 24 hours, at $2.82 per share.